Dose-ranging study of riluzole in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L, Bensimon, G, Meininger, V, Leigh, P.N, Guillet, P·1996·The Lancet

DOI 10.1016/s0140-6736(96)91680-3

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(96)91680-3

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Amyotrophic lateral sclerosis
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Glutamate as a neurotransmitter in the brain: review of physiology and pathology
Meldrum, B. S. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.4.1007s · Cited by 1,667
EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., & Shaw, P. J. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.152 · Cited by 615
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916945 · Cited by 536
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
Prognosis in amyotrophic lateral sclerosis: A population-based study
del Aguila, M. A., Longstreth, W. T., McGuire, V., Koepsell, T. D., & van Belle, G. (2003) · Neurology · doi:10.1212/01.wnl.0000049472.47709.3b · Cited by 469
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451
A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade?: Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating ALS
Bellingham, M. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00116.x · Cited by 388
II. Glutamine and glutamate
Tapiero, H., Mathé, G., Couvreur, P., & Tew, K. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00285-8 · Cited by 369
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
The glutamate antagonist Riluzole suppresses intracortical facilitation
Liepert, J., Schwenkreis, P., Tegenthoff, M., & Malin, J. P. (1997) · Journal of Neural Transmission · doi:10.1007/bf01294721 · Cited by 274
Glutamate Transporters and the Excitotoxic Path to Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis
Foran, E., & Trotti, D. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2444 · Cited by 268
Early symptom progression rate is related to ALS outcome: A prospective population-based study
Chiò, A., Mora, G., Leone, M., Mazzini, L., Cocito, D., Giordana, M. T., Bottacchi, E., & Mutani, R. (2002) · Neurology · doi:10.1212/wnl.59.1.99 · Cited by 266
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30054-1 · Cited by 259
Self-citation
ALSFRS-R score and its ratio: A useful predictor for ALS-progression
Kollewe, K., Mauss, U., Krampfl, K., Petri, S., Dengler, R., & Mohammadi, B. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.07.016 · Cited by 253
Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28
Zürcher, N. R., Loggia, M. L., Lawson, R., Chonde, D. B., Izquierdo-Garcia, D., Yasek, J. E., Akeju, O., Catana, C., Rosen, B. R., Cudkowicz, M. E., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.01.009 · Cited by 226
“Riluzole, the only FDA-approved treatment provides a modest survival benefit (Lacomblez et al., 1996), S-R, amyotrophic lateralsclerorate; MR,magnetic resonance; ron emission tomography; SUV, in;UMNB, uppermotorneuron search Institute, Massachusetts on, 02114 MA, USA.”
Background
Untitled work
Ince (1998) · doi:10.1046/j.1365-2990.1998.00108.x · Cited by 224
Diagnosis and management of motor neurone disease
McDermott, C. J., & Shaw, P. J. (2008) · BMJ · doi:10.1136/bmj.39493.511759.be · Cited by 220
Riluzole enhances expression of brain‐derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus
Katoh, R., Asano, T., Ueda, H., Morishita, R., Takeuchi, I. K., Inaguma, Y., & Kato, K. (2002) · The FASEB Journal · doi:10.1096/fj.02-0143fje · Cited by 193
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis
Paganoni, S., Hendrix, S., Dickson, S. P., Knowlton, N., Macklin, E. A., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., et al. (2021) · Muscle & Nerve · doi:10.1002/mus.27091 · Cited by 180
Astrocyte senescence promotes glutamate toxicity in cortical neurons
Limbad, C., Oron, T. R., Alimirah, F., Davalos, A. R., Tracy, T. E., Gan, L., Desprez, P.-Y., & Campisi, J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227887 · Cited by 183
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177
Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial
Kaufmann, P., Levy, G., Montes, J., Buchsbaum, R., Barsdorf, A. I., Battista, V., Arbing, R., Gordon, P. H., Mitsumoto, H., Levin, B., et al. (2007) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960600888156 · Cited by 145
ALS and other motor neuron diseases
Tiryaki, E., & Horak, H. A. (2014) · Continuum · doi:10.1212/01.con.0000455886.14298.a4 · Cited by 143
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141
Self-citation
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
(2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70037-1 · Cited by 132
Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression
Bruneteau, G., Simonet, T., Bauché, S., Mandjee, N., Malfatti, E., Girard, E., Tanguy, M.-L., Behin, A., Khiami, F., Sariali, E., et al. (2013) · Brain · doi:10.1093/brain/awt164 · Cited by 131
Self-citation
A phase II–III trial of olesoxime in subjects with amyotrophic lateral sclerosis
Lenglet, T., Lacomblez, L., Abitbol, J. L., Ludolph, A., Mora, J. S., Robberecht, W., Shaw, P. J., Pruss, R. M., Cuvier, V., Meininger, V., et al. (2014) · European Journal of Neurology · doi:10.1111/ene.12344 · Cited by 130
Self-citation
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases
Friede, T., Röver, C., Wandel, S., & Neuenschwander, B. (2017) · Biometrical Journal · doi:10.1002/bimj.201500236 · Cited by 128
Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial
Weber, M., Goldman, B., & Truniger, S. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.200642 · Cited by 116
Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
Ilieva, H., Vullaganti, M., & Kwan, J. (2023) · BMJ · doi:10.1136/bmj-2023-075037 · Cited by 111
Suicide among patients with amyotrophic lateral sclerosis
Fang, F., Valdimarsdóttir, U., Fürst, C. J., Hultman, C., Fall, K., Sparén, P., & Ye, W. (2008) · Brain · doi:10.1093/brain/awn161 · Cited by 100
Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease
Orrell, R. W., Lane, R. J., & Ross, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002829.pub4 · Cited by 98
Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder
Grant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84
Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial
Verstraete, E., Veldink, J. H., Huisman, M. H. B., Draak, T., Uijtendaal, E. V., van der Kooi, A. J., Schelhaas, H. J., de Visser, M., van der Tweel, I., & van den Berg, L. H. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-302021 · Cited by 78
Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration
De Paola, M., Mariani, A., Bigini, P., Peviani, M., Ferrara, G., Molteni, M., Gemma, S., Veglianese, P., Castellaneta, V., Boldrin, V., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00020 · Cited by 75
Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis
Jiang, Z., Wang, W., Perry, G., Zhu, X., & Wang, X. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0037-x · Cited by 66
Factors supporting quality of life over time for individuals with amyotrophic lateral sclerosis: the role of positive self-perception and religiosity
Bremer, B. A., Simone, A.-L., Walsh, S., Simmons, Z., & Felgoise, S. H. (2004) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2802_7 · Cited by 58
An Investigation of the Neuroprotective Effects of Tetracycline Derivatives in Experimental Models of Retinal Cell Death
Baptiste, D. C., Hartwick, A. T. E., Jollimore, C. A. B., Baldridge, W. H., Seigel, G. M., & Kelly, M. E. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001081 · Cited by 55
The cortisol awakening response in amyotrophic lateral sclerosis is blunted and correlates with clinical status and depressive mood
Roozendaal, B., Kim, S., Wolf, O. T., Kim, M. S., Sung, K.-K., & Lee, S. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.04.013 · Cited by 31

Authors: Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P.
Venue: The Lancet
Publisher: Elsevier BV
Published: 1996-05
Volume: 347
Issue: 9013
Pages: 1425-1431
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(96)91680-3
OpenAlex: W2085165928
Cited by: 1,301
References: 0
FWCI: 40.09
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review